#LungCancerFAQ
LightNews LightNews
cizzlebio.com
The CIZ1B Biomarker Blood Test for Lung Cancer is designed to complement LDCT and other clinical information, not replace them.
Results should be interpreted by a healthcare provider as part of a comprehensive assessment.
Learn more: buff.ly/m5AToVS
#CizzleBio #CIZ1B #LungCancerFAQ #PatientEducation
Cizzle Bio carousel introducing frequently asked questions about the CIZ1B Biomarker Blood Test for earlier lung cancer detection. The graphic features a blood sample tube beneath a large question mark. “Does CIZ1B replace LDCT?” No. The CIZ1B Biomarker Blood Test is designed to complement low-dose computed tomography and other standard-of-care approaches, not replace them. “Does a CIZ1B result confirm or rule out cancer?” No. The test provides biomarker information that must be interpreted with other clinical information as part of a comprehensive assessment. “How is the test performed?” A small blood sample is collected, securely packaged and transported, then processed and analyzed by a CLIA-certified laboratory partner.
August 7, 2026 at 10:28 PM